Das S

Compass Pathways, Inc (A Subsidiary of Compass Pathways Plc), New York, NY, USA.

3 papers

ArticlePsilocybin

Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.

McGowan NM, Rucker JJ, Yehuda R +6

Europe PMC2026
ArticlePsilocybin

Bedside to bench: the outlook for psychedelic research.

Acero VP, Cribas ES, Browne KD +5

Europe PMC2023
ArticleLSD

Lysergic acid diethylamide: a drug of 'use'?

Das S, Barnwal P, Ramasamy A +2

Europe PMC2016